Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).

作者： Kim Leitzel , Suhail M Ali , Lois E Shepherd , Wendy R Parulekar , Liting Zhu

DOI: 10.1200/JCO.2018.36.15_SUPPL.1031

关键词: Trastuzumab 、 Metastatic breast cancer 、 First line 、 Anti her2 、 PD-L1 、 Oncology 、 Medicine 、 Internal medicine

摘要: 1031Background: In MA.31 the lapatinib-taxane combination led to shorter PFS than trastuzumab-taxane in HER2+ metastatic breast cancer. We previously reported positive prognostic utility of pre...

ascopubs.org 本地加速

sci-hub.st HTML 下载加速

参考文章(0)

Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).

来源期刊

我的账户

Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).

来源期刊

相似文章 3

Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.

PD-1 and PD-L1 are diagnostic biomarkers and PD-L1 a promising therapeutic target in HER2-positive and triple negative normal-like feline mammary carcinoma subtypes

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.

我的账户